ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1165

Clinical Characteristics of Patients with Late-Onset Familial Mediterranean Fever in Japan

Dai Kishida1, Masahide Yazaki1, Akinori Nakamura1, Ayako Tsuchiya-Suzuki1, Yasuhiro Shimojima2 and Yoshiki Sekijima1, 1Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan, 2Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: familial Mediterranean fever and genetic disorders, Japanese

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Familial Mediterranean fever (FMF) is an auto-inflammatory disease characterized by recurrent episodes of fever and polyserositis. Most patients have their first febrile attack before the age of 20. Elderly onset (after 40 years) is very rare, but we do encounter these patients sometimes. Therefore, the aim of this study was to evaluate the demographic, clinical, and genetic characteristics of late-onset FMF patients in the Japanese population.

Methods: We analyzed clinical features and mutations in the MEFV gene of 384 patients, who were referred to our laboratory (Department of Medicine [Neurology and Rheumatology], Shinshu University School of Medicine) between September 2003 and September 2016. All patients were clinically diagnosed with FMF by the Tel-Hashomer criteria. Patients were divided into three groups based on the age of disease onset; group I: 19 years and younger (early-onset group), group II: 20–39 years, group III: 40 years and older (late-onset group). Mutation analysis of the MEFV gene was performed by direct sequencing of the product of polymerase chain reaction amplification for hotspot regions (exons 1, 2, 3, 5, and 10). Differences between categorical variables were analyzed using chi-square test with Bonferroni correction. Continuous variables were evaluated with Kruskal-Wallis test and multiple comparison.

Results: The study enrolled 63 patients (16.4%) who experienced their first FMF attack when older than 40 years. In this patient group, high fever (90.5%) was the most common clinical finding. In contrast, the percentage of patients with peritonitis (66.2% in group I, 66.8% in group II, 34.9% in group III) and pleuritis (47.0% in group I, 36.5% in group II, 27.0% in group III) was significantly lower in late-onset patients compared with early-onset patients. In the late-onset group, the frequency of patients having a mutation in the MEFV gene (57.1%) and a mutation in exon 10 (12.7%), which induces a severe clinical FMF phenotype, was significantly lower than in early-onset patients. The response to colchicine therapy was good (88.6%) and similar in all groups. Family history of FMF was less frequent in the late-onset group.

Conclusion: In Japan, there are a number of FMF patients with late-onset. Our observation indicates that they have a milder form of the disease with less frequent peritonitis and pleuritis and a good response to colchicine treatment. However, careful differential diagnosis may be needed because they have a lower prevalence of the MEFV gene mutation, especially in exon 10.


Disclosure: D. Kishida, None; M. Yazaki, None; A. Nakamura, None; A. Tsuchiya-Suzuki, None; Y. Shimojima, None; Y. Sekijima, None.

To cite this abstract in AMA style:

Kishida D, Yazaki M, Nakamura A, Tsuchiya-Suzuki A, Shimojima Y, Sekijima Y. Clinical Characteristics of Patients with Late-Onset Familial Mediterranean Fever in Japan [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/clinical-characteristics-of-patients-with-late-onset-familial-mediterranean-fever-in-japan/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-characteristics-of-patients-with-late-onset-familial-mediterranean-fever-in-japan/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology